Needle Free Platform PassPort's transdermal system enables needle-free delivery for small molecules, peptides, oligonucleotides, and proteins, offering opportunities to reposition approved therapeutics or enable new administration routes for NCEs. This provides a compelling value proposition for pharma partners seeking patient-friendly options and improved adherence; ideal targets include injectables with adherence challenges or high dosing burdens.

Transdermal Momentum Recent collaboration activity, including engagement with Arcturus Therapeutics to evaluate transdermal mRNA delivery, signals growing market interest in non-invasive delivery platforms. This opens doors to engage biotech and gene-therapy developers exploring alternative modalities and pursue pilot licensing or sponsored research arrangements.

Flexible Licensing As a small, early-stage company with a lean footprint, PassPort can offer flexible, milestone-driven licensing or co-development partnerships with larger pharma to reduce upfront risk while enabling portfolio expansion through its platform.

Regional Partnerships Based in San Diego, the company sits in a dense biotech hub, enabling proximity-based outreach to local biotechs, CMOs, and contract development partners to accelerate pilots, scale manufacturing, and navigate regulatory support for early-stage programs.

Repurposing Focus The PassPort System supports drug repurposing by enabling alternative administration for approved products, suggesting revenue opportunities through licensing or collaborations with pharma interested in extending product lifecycles and improving patient experience via non-invasive delivery.